|
BREAKING NEWS: Aqueous Pharma announces new technology to enhance human tear production. This is product code APL-106 and several clinical studies, conducted in Europe, substantiate the efficacy of the active ingredient. This is early stage but if everything falls into place; APL-106 could easily be a "game changer".
|
|
 |
|
|
4 Uniquely Effective Artificial Tears
|
FreshKote (APL-105) - New 3-Layered Artificial Tear; especially effective for "evaporative" dry eye but helpful in all levels of dry eye. FDA Monograph compliant and cleared for OTC Marketing by the British MHRA. EU-wide approval granted in November 2006 via CE Mark. European Patent Office and the USPTO have approved the patent applications. FreshKote trademark applications approved by the USPTO and the EU Trademark Office.
|
|
- NutraTear - for mild dry eye/computer vision syndrome. Enhanced with red Vitamin B12 and synergistic blending of 2 polymers.
- Dakrina - for moderate to severe dry eye. Proven highly effective for Sjogren's dry eye in Duke University Study. Contains only polymer-complexed Vitamin A - bioavailable to the ocular surface cells - with synergistic blending of 3 polymers.
- Dwelle - Synergistic blending of 3 polymers for Moderate dry eye. Also especially helpful for use at bedtime instead of 'greasy' ointments.
- Each of the 4 tears is preserved with the highly effective and totally non-irritating polixetonium; a patented ophthalmic solution preservative.
- 12 clinical studies have validated the unprecedented efficacy and safety of these products. In addition, an ongoing open evaluation (monitored by the Dry Eye Institute) in hundreds of dry eye patients has proven the long term efficacy & safety.
|
|
|
|
|
